Search results for: Zhongsheng Tong

Items from 1 to 19 out of 19 results

article

Chinese expert consensus on management of antifungal‐resistant dermatophytoses (2024 edition)

Guanzhao Liang, Xiaofang Li, Ruoyu Li, Hai Wen, more

Mycoses > 67 > 9 > n/a - n/a

Antifungal‐resistant dermatophytes (ARD) infection is a hotspot issue in clinical microbiology and the dermatology field. Trichophyton indotineae as the dominant species of dermatophyte with terbinafine‐resistance or multidrug resistance, is easy to be missed detection clinically, which brings severe challenges to diagnosis and treatment. ARD infection cases have emerged in China, and it predicts...

article

Epidemiologic features and therapeutic strategies of kerion: A nationwide multicentre study

Ruixin Deng, Xiaoqing Chen, Dongyan Zheng, Yuanyuan Xiao, more

Mycoses > 67 > 6 > n/a - n/a

Background Kerion is a severe type of tinea capitis that is difficult to treat and remains a public health problem. Objectives To evaluate the epidemiologic features and efficacy of different treatment schemes from real‐world experience. Methods From 2019 to 2021, 316 patients diagnosed with kerion at 32 tertiary Chinese hospitals were enrolled. We analysed the data of each patient, including...

article

Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study

Yiqun Li, Zhongsheng Tong, Xinhong Wu, Quchang Ouyang, more

International Journal of Cancer > 153 > 10 > 1809 - 1818

Pyrotinib, an irreversible pan‐ErbB inhibitor, has been approved for treating HER2‐positive advanced breast cancer in China. We conducted a nationwide, prospective observational study to examine the real‐world data of pyrotinib‐based therapy in this population. Patients from 61 sites across China were included. Pyrotinib‐based regimens were prescribed at local physician's discretion. Demographics,...

article

A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments

Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, more

International Journal of Cancer > 152 > 10 > 2134 - 2144

Refractory or relapsing metastatic triple‐negative breast cancer (mTNBC) has a poor prognosis. Sacituzumab govitecan (SG) is a novel antibody‐drug conjugate, targeting human trophoblast cell‐surface antigen 2 (Trop‐2). This is the first report of SG's efficacy and safety in Chinese patients with mTNBC. EVER‐132‐001 (NCT04454437) was a multicenter, single‐arm, Phase IIb study in Chinese patients with...

article

Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

Binghe Xu, Xichun Hu, Jifeng Feng, Cuizhi Geng, more

Cancer > 126 > S16 > 3867 - 3882

Breast cancer is the most common malignant tumor among women in the world. In 2005, there were approximately 272,000 new cases diagnosed and more than 70,000 deaths from breast cancer in China. Of the patients who are newly diagnosed with breast cancer each year, approximately 3% to 10% have distant metastases at the time of diagnosis. Of those who have early stage disease at diagnosis, from 30% to...

article

Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells

YeHui Shi, Wei Zhang, Lixin Li, ZhongSheng Tong, more

Medicinal Chemistry Research > 2018 > 27 > 11-12 > 2437-2445

A series of triazolo-lapatinib hybrids were synthesized via copper (II)-oxide nanoparticle (Cu₂O-NP)-catalyzed azide-alkyne cycloaddition. The ability of these compounds to reduce the viability of breast cancer SKBR3 and SUM159 cells and stem cell-like KG-1a leukemia cells was subsequently evaluated. Compared with lapatinib, compounds 6c–f were more potent than lapatinib against the three cell lines...

article

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, more

The Lancet Oncology > 2017 > 18 > 12 > 1688-1700

ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings. In this ongoing randomised, double-blind,...

article

36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified

Shuling Wang, Weidong Li, Fang Wang, Yun Niu, more

Pathology - Research and Practice > 2017 > 213 > 4 > 310-315

The aim of this study was to investigate the clinicopathological characteristic of adenoid cystic carcinoma (ACC).The clininopathological features, along with relapse free survival(RFS) and overall survival(OS) of 36 patients with ACC were retrospectively investigated and compared with those of 108 grade 1 invasive ductal carcinoma not-otherwise-specified (G1-IDC-NOS) patients.Most cases of ACC were...

article

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

Pin Zhang, Tao Sun, Qingyuan Zhang, Zhongyu Yuan, more

The Lancet Oncology > 2017 > 18 > 3 > 371-383

Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus capecitabine alone in patients with metastatic breast cancer. We did a multicentre, open-label, superiority, phase 3, randomised controlled trial in...

article

Preparation of polyclonal antibodies for nateglinide (NTG) and development of a sensitive chemiluminescent immunoassay to detect NTG in tablets and serum

Lei Zheng, Jing Wang, Jie Zhang, Zhaorui Song, more

Talanta > 2016 > 146 > Complete > 483-489

In this study, we prepared polyclonal antibodies against anti-diabetic drug nateglinide (NTG), and established a sensitive chemiluminescent immunoassay (CLIA) to detect NTG in tablets and serum. Two kinds of immunogens were synthesized using ethylcarbodiimide (EDC)/hydroxysuccinimide (NHS) and carbonyldiimidazole (CDI)/4-dimethylaminopyridine (DMAP) as coupling reagents respectively. When activated...

article

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Pin Zhang, Zhongsheng Tong, Fuguo Tian, Yongsheng Wang, more

Journal of Hematology & Oncology > 2016 > 9 > 1 > 1-9

Background The treatment of metastatic breast cancer (MBC) remains a great clinical challenge as drug resistance frequently develops. Alternative agents that can overcome drug resistance would offer new therapeutic options. The primary aim of this phase II study was to evaluate the efficacy and safety of utidelone as a monotherapy or in combination with capecitabine in metastatic breast cancer patients...

article

EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells

Chen Wang, Kazim Husain, Anying Zhang, Barbara A. Centeno, more

The Journal of Nutritional Biochemistry > 2015 > 26 > 8 > 797-807

The anticancer activity of δ-tocotrienol, a bioactive vitamin E present in whole grain cereals, annatto beans and palm fruit, is strongly dependent on its effect on the induction of apoptosis. δ-Tocotrienol-induced apoptosis is associated with consistent induction in the expression of the proapoptotic protein Bcl-2-associated X protein (Bax). The molecular mechanism by which δ-tocotrienol regulates...

article

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu, Zefei Jiang, more

International Journal of Cancer > 135 > 8 > 1961 - 1969

Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretreated patients with metastatic triple negative breast cancer (mTNBC) in China. Phase IIa was first performed...

article

Inhibition of AMPK/Autophagy Potentiates Parthenolide‐Induced Apoptosis in Human Breast Cancer Cells

Can Lu, Wenwen Wang, Yongsheng Jia, Xiaodong Liu, more

Journal of Cellular Biochemistry > 115 > 8 > 1458 - 1466

Parthenolide is the main bioactive component in feverfew, a common used herbal medicine, and has been extensively studied in relation to its anti‐cancer properties. However there have been very few in‐depth studies of the activities of this compound at the molecular level. Here, we showed that parthenolide increased reactive oxygen species (ROS), induced cell death, activated AMPK and autophagy, and...

article

CARD9 mutations linked to subcutaneous phaeohyphomycosis and TH17 cell deficiencies

Xiaowen Wang, Wenyan Wang, Zhimiao Lin, Xiaolin Wang, more

The Journal of Allergy and Clinical Immunology > 2014 > 133 > 3 > 905-908.e3

article

Generalized Subcutaneous Phaeohyphomycosis Caused by Phialophora verrucosa: Report of a Case and Review of Literature

Zhongsheng Tong, Sharon C.-A. Chen, Liuqing Chen, Bilin Dong, more

Mycopathologia > 2013 > 175 > 3-4 > 301-306

We report a case of subcutaneous phaeohyphomycosis due to Phialophora verrucosa in a 64-year-old Chinese farmer suffering from CD4+ lymphopenia. He presented with diffuse and infiltrated plaques involving the entire face including the eyes, neck, occiput, and extending to the dorsal regions of his torso. The patient is notable for the discrete multifocal nature of the illness in the absence of disseminated...

article

The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro

Chunfang Hao, Sen Wei, Zhongsheng Tong, Shufen Li, more

Tumor Biology > 2012 > 33 > 4 > 1159-1167

The purpose of this study was to investigate the effect of Raf kinase inhibitor protein (RKIP) on the growth, proliferation, invasion and metastasis of triple-negative breast cancer (TNBC) cells to provide experimental evidence for developing future therapies against human TNBC. The pcDNA3.1-RKIP eukaryotic expression vector was constructed and transfected into the TNBC cell line MDA-MB-231. The alterations...

article

The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model

Chunfang Hao, Yehui Shi, Jinpu Yu, Xueqing Wei, more

Molecular and Cellular Biochemistry > 2012 > 367 > 1-2 > 93-102

This study aimed at analyzing the therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model and preliminarily explore the mechanism of RANTES in malignant ascites to provide an important reference for applying chemokines in anti-tumor therapy. The murine H22 hepatoma ascites model was used. Three treatment groups were analyzed: a RANTES treatment group, an IL-2 control group,...

article

A practical method for subtyping of Streptococcus agalactiae serotype III, of human origin, using rolling circle amplification

Zhongsheng Tong, Fannrong Kong, Bin Wang, Xianyu Zeng, more

Journal of Microbiological Methods > 2007 > 70 > 1 > 39-44

Group B streptococcus (GBS; Streptococcus agalactiae) serotype III is one of the most common and virulent serotypes of the species. It can be divided into several subtypes, which vary in their distribution among invasive isolates from different patient groups. In this study, we used 91 well-characterized GBS serotype III isolates to compare three subtyping methods, and developed a novel padlock probe...

Filter options

Publication date

Last 3 months (1)
Last year (2)
Last 3 years (4)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Zhongsheng Tong

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options